Roivant Sciences Company Insiders

ROIV Stock  USD 12.71  0.02  0.16%   
Roivant Sciences' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Roivant Sciences suggests that vertually all insiders are panicking. Roivant Sciences employs about 908 people. The company is managed by 19 executives with a total tenure of roughly 2119 years, averaging almost 111.0 years of service per executive, having 47.79 employees per reported executive.

Roivant Sciences' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-11-20Eric VenkerDisposed 100000 @ 11.32View
2024-10-21Eric VenkerDisposed 100000 @ 11.65View
2024-09-26Financial Lp QvtDisposed 876000 @ 11.82View
2024-09-24Keith S ManchesterDisposed 368052 @ 11.62View
2024-09-23Rakhi KumarDisposed 250000 @ 11.89View
2024-02-09Eric VenkerDisposed 96950 @ 10.92View
2024-01-02Vivek RamaswamyDisposed 3000000 @ 11.05View
Monitoring Roivant Sciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roivant Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Roivant Stock please use our How to Invest in Roivant Sciences guide.

Roivant Sciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.1844) % which means that it has lost $0.1844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.2896 %, meaning that it created $1.2896 on every $100 dollars invested by stockholders. Roivant Sciences' management efficiency ratios could be used to measure how well Roivant Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.64 in 2024. Return On Capital Employed is likely to climb to 0.64 in 2024. At this time, Roivant Sciences' Asset Turnover is fairly stable compared to the past year.
Common Stock Shares Outstanding is likely to drop to about 610.3 M in 2024. Net Loss is likely to climb to about (862.7 M) in 2024

Roivant Sciences Workforce Comparison

Roivant Sciences is rated second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 15,905. Roivant Sciences holds roughly 908 in number of employees claiming about 6% of equities under Health Care industry.

Roivant Sciences Profit Margins

The company has Profit Margin (PM) of 37.25 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (74.46) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $74.46.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.950.7759
Fairly Up
Slightly volatile

Roivant Sciences Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Roivant Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Roivant Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Roivant Sciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
0.4545
5
11
 205,147 
 448,035 
2024-09-01
0.6765
23
34
 38,725,865 
 10,481,120 
2024-06-01
0.2917
7
24
 577,845 
 41,242,883 
2024-03-01
0.2
7
35
 1,224,081 
 128,615,479 
2023-12-01
0.3448
10
29
 1,589,822 
 3,838,106 
2023-09-01
0.5217
48
92
 2,374,705 
 41,871,998 
2023-06-01
0.4615
30
65
 3,012,554 
 46,285,932 
2023-03-01
0.1333
2
15
 4,457 
 16,216,673 
2022-12-01
0.129
4
31
 4,007,794 
 24,196,828 
2022-09-01
1.5556
14
9
 995,843 
 117,414 
2022-06-01
1.4444
13
9
 103,211,074 
 340,550 
2021-12-01
0.0189
1
53
 313,419 
 85,897,655 

Roivant Sciences Notable Stakeholders

A Roivant Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Roivant Sciences often face trade-offs trying to please all of them. Roivant Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Roivant Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
PharmD MDPresident COOProfile
Mayukh MDChief PresidentProfile
Amy MaheryChief OfficerProfile
Matthew GlineCEO DirectorProfile
Marianne RomeoHead ManagementProfile
Huafeng XuChief OfficerProfile
Josh ChenGeneral CounselProfile
Matt MaisakChief PlatformsProfile
Vivek RamaswamyFounder ChairmanProfile
Alex GasnerExecutive HealthProfile
Jo ChenGeneral CounselProfile
Drew KramerChief OfficerProfile
Kelly GraffHead PeopleProfile
Richard PulikChief OfficerProfile
Deya MDChief OfficerInResidenceProfile
Srini RamanathanChief OfficerProfile
Rakhi KumarChief OfficerProfile
Josh JDGeneral CounselProfile
David MDChief DermavantProfile

About Roivant Sciences Management Performance

The success or failure of an entity such as Roivant Sciences often depends on how effective the management is. Roivant Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Roivant management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Roivant management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.61  0.64 
Return On Capital Employed 0.61  0.64 
Return On Assets 0.60  0.63 
Return On Equity 0.73  0.77 
Please note, the imprecision that can be found in Roivant Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Roivant Sciences. Check Roivant Sciences' Beneish M Score to see the likelihood of Roivant Sciences' management manipulating its earnings.

Roivant Sciences Workforce Analysis

Traditionally, organizations such as Roivant Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Roivant Sciences within its industry.

Roivant Sciences Manpower Efficiency

Return on Roivant Sciences Manpower

Revenue Per Employee137.4K
Revenue Per Executive6.6M
Net Income Per Employee4.7M
Net Income Per Executive222.7M
Working Capital Per Employee7.1M
Working Capital Per Executive340.3M

Additional Tools for Roivant Stock Analysis

When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.